{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:32Z","timestamp":1786982132935,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Deng Feng project of Foshan First People\u2019s Hospital","award":["2019A008"],"award-info":[{"award-number":["2019A008"]}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","award":["2016A020213001"],"award-info":[{"award-number":["2016A020213001"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515010855"],"award-info":[{"award-number":["2020A1515010855"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971355"],"award-info":[{"award-number":["31971355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11912-022-01355-4","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T02:02:52Z","timestamp":1672452172000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4396-0314","authenticated-orcid":false,"given":"Bernardo","family":"Cavallazzi Sebold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-7767","authenticated-orcid":false,"given":"Tianfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"issue":"7042","key":"1355_CR1","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nature03724","volume":"435","author":"CC Goodnow","year":"2005","unstructured":"Goodnow CC, Sprent J, de St Fazekas, Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nat. 2005;435(7042):590\u20137.","journal-title":"Nat"},{"issue":"21","key":"1355_CR2","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","volume":"361","author":"EO Glocker","year":"2009","unstructured":"Glocker EO, Kotlarz D, Boztug K, Gertz EM, Sch\u00e4ffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033\u201345.","journal-title":"N Engl J Med"},{"issue":"4","key":"1355_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/carcin\/22.4.665","volume":"22","author":"S Sturlan","year":"2001","unstructured":"Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J, et al. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinog. 2001;22(4):665\u201371.","journal-title":"Carcinog"},{"issue":"10","key":"1355_CR4","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1080\/21645515.2020.1717185","volume":"16","author":"G Ni","year":"2020","unstructured":"\u2022 Ni G, Zhang L, Yang X, Li H, Ma B, Walton S, et al. Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task. Hum Vaccin Immunother. 2020;16(10):2328\u201332. (This article reviewed the current advances in temporal IL-10 signaling blockade enhances vaccine-induced tumor regression by CD8+ T cells and discussed the complexity of IL-10 manipulation for cancer therapy.)","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1355_CR5","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.4049\/jimmunol.155.6.3112","volume":"155","author":"M Giovarelli","year":"1995","unstructured":"Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol. 1995;155(6):3112\u201323.","journal-title":"J Immunol"},{"issue":"1","key":"1355_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4049\/jimmunol.157.1.231","volume":"157","author":"RM Berman","year":"1996","unstructured":"Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol. 1996;157(1):231\u20138.","journal-title":"J Immunol"},{"issue":"5","key":"1355_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","volume":"34","author":"A Naing","year":"2018","unstructured":"Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, et al. PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell. 2018;34(5):775-91.e3.","journal-title":"Cancer Cell"},{"issue":"14","key":"1355_CR8","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-12-0721","volume":"72","author":"J Emmerich","year":"2012","unstructured":"Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, et al. IL-10 Directly activates and expands tumor-resident CD8+ T cells without de novo infiltration from secondary lymphoid organs. Can Res. 2012;72(14):3570\u201381.","journal-title":"Can Res"},{"issue":"6","key":"1355_CR9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"B Mumm John","year":"2011","unstructured":"Mumm John B, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 Elicits IFN\u03b3-dependent tumor immune surveillance. Cancer Cell. 2011;20(6):781\u201396.","journal-title":"Cancer Cell"},{"key":"1355_CR10","doi-asserted-by":"crossref","unstructured":"\u2022 Saraiva M, Vieira P, O\u2019Garra A. Biology and therapeutic potential of interleukin-10.\u00a0J Exp Med (2020);217(1): e20190418. (This review discussed the current understanding of the regulation of IL-10 production and of the molecular pathways associated with IL-10 responses, described its nonclassic roles, and covered its therapeutic potential in the context of different diseases.)","DOI":"10.1084\/jem.20190418"},{"issue":"2","key":"1355_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.184.2.579","volume":"184","author":"LM Zheng","year":"1996","unstructured":"Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med. 1996;184(2):579\u201384.","journal-title":"J Exp Med"},{"issue":"4","key":"1355_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1355_CR13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.4049\/jimmunol.147.2.528","volume":"147","author":"WF Chen","year":"1991","unstructured":"Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol. 1991;147(2):528\u201334.","journal-title":"J Immunol"},{"issue":"5","key":"1355_CR14","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.4049\/jimmunol.165.5.2783","volume":"165","author":"FN Lauw","year":"2000","unstructured":"Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJH, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol. 2000;165(5):2783\u20139.","journal-title":"J Immunol"},{"issue":"3","key":"1355_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.4049\/jimmunol.155.3.1079","volume":"155","author":"DS Finbloom","year":"1995","unstructured":"Finbloom DS, Winestock KD. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol. 1995;155(3):1079\u201390.","journal-title":"J Immunol"},{"issue":"7","key":"1355_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/bies.201300004","volume":"35","author":"JB Mumm","year":"2013","unstructured":"Mumm JB, Oft M. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-\u03b3-mediated CD8(+) T cell cytotoxicity. BioEssays. 2013;35(7):623\u201331.","journal-title":"BioEssays"},{"issue":"2","key":"1355_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1006\/cimm.1996.0269","volume":"173","author":"SR Smith","year":"1996","unstructured":"Smith SR, Terminelli C, Denhardt G, Narula S, Thorbecke GJ. Administration of interleukin-10 at the time of priming protects Corynebacterium parvum-primed mice against LPS- and TNF-alpha-induced lethality. Cell Immunol. 1996;173(2):207\u201314.","journal-title":"Cell Immunol"},{"issue":"2","key":"1355_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/blood.V87.2.699.bloodjournal872699","volume":"87","author":"RD Huhn","year":"1996","unstructured":"Huhn RD, Radwanski E, O\u2019Connell SM, Sturgill MG, Clarke L, Cody RP, et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood. 1996;87(2):699\u2013705.","journal-title":"Blood"},{"issue":"2","key":"1355_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cellimm.2014.12.012","volume":"293","author":"G Ni","year":"2015","unstructured":"Ni G, Wang T, Walton S, Zhu B, Chen S, Wu X, et al. Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol. 2015;293(2):126\u20139.","journal-title":"Cell Immunol"},{"issue":"11","key":"1355_CR20","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1023\/B:PHAM.0000048199.94510.b0","volume":"21","author":"H Rachmawati","year":"2004","unstructured":"Rachmawati H, Beljaars L, Reker-Smit C, Van Loenen-Weemaes AM, Hagens WI, Meijer DK, et al. Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. Pharm Res. 2004;21(11):2072\u20138.","journal-title":"Pharm Res"},{"issue":"2","key":"1355_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1124\/dmd.111.042531","volume":"40","author":"HM Alvarez","year":"2012","unstructured":"Alvarez HM, So OY, Hsieh S, Shinsky-Bjorde N, Ma H, Song Y, et al. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice. Drug Metab Dispos. 2012;40(2):360\u201373.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1355_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2012.05.041","volume":"162","author":"A Mattos","year":"2012","unstructured":"Mattos A, de Jager-Krikken A, de Haan M, Beljaars L, Poelstra K. PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl4-induced fibrogenesis in mice. J Control Release. 2012;162(1):84\u201391.","journal-title":"J Control Release"},{"key":"1355_CR23","unstructured":"Lee S, Wylie DC, Cannon-Carlson SV. Pegylated interleukin-10. US Grant No. US7052686B2. 2000."},{"key":"1355_CR24","unstructured":"Oft M, Sheppard C, Mumm J, Linling W. Merck Sharp & Dohme. Pegylated IL-10 for use in treating cancer or tumor. European patent Grant No. EP2821078A1. 2015."},{"issue":"2","key":"1355_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ijc.33556","volume":"149","author":"NM Tannir","year":"2021","unstructured":"\u2022 Tannir NM, Papadopoulos KP, Wong DJ, Aljumaily R, Hung A, Afable M, et al. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021;149(2):403\u20138. (This study reported the phase I\/Ib multi-cohort dose escalation IVY clinical trial results of pegilodecakin+ pazopanib, and final results for monotherapy and long-term follow-up with pegilodecakin + antiprogrammed cell death 1 (anti-PD-1) inhibitors.)","journal-title":"Int J Cancer"},{"issue":"2","key":"1355_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jtho.2020.10.001","volume":"16","author":"D Spigel","year":"2021","unstructured":"\u2022 Spigel D, Jotte R, Nemunaitis J, Shum M, Schneider J, Goldschmidt J, et al. Randomized phase 2 studies of checkpoint inhibitors alone or in combination with pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2). J Thorac Oncol\u202f: Off Publ Int Assoc Study Lung Cancer. 2021;16(2):327\u201333. (This study reported the results of randomized phase II clinical trial of checkpoint inhibitors alone or in combination with pegilodecakin in patients with metastatic non-small cell lung cancer; more definitive data on toxicity and efficacy (or lack thereof), and preliminary immune biomarker information were provided.)","journal-title":"J Thorac Oncol : Off Publ Int Assoc Study Lung Cancer"},{"issue":"10","key":"1355_CR27","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO.20.02232","volume":"39","author":"JR Hecht","year":"2021","unstructured":"\u2022 Hecht JR, Lonardi S, Bendell J, Sim HW, Macarulla T, Lopez CD, et al. Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA). J Clin Oncol. 2021;39(10):1108\u201318. (The study reported that results of phase III clinical that compared efficacy and safety of adding pegilodecakin with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following progression on first-line gemcitabine-containing therapy with metastatic pancreatic ductal adenocarcinoma.)","journal-title":"J Clin Oncol"},{"issue":"7","key":"1355_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/bies.201300004","volume":"35","author":"JB Mumm","year":"2013","unstructured":"Mumm JB, Oft M. Pegylated IL-10 induces cancer immunity. BioEssays. 2013;35(7):623\u201331.","journal-title":"BioEssays"},{"key":"1355_CR29","unstructured":"Blaisdell SJ, Cutler CM, Paporello BC, Ambrogelly A. Mono- and di-peg il-10 production; and uses. European Patent Grant No. EP3348281A1. 2018."},{"issue":"6","key":"1355_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"JB Mumm","year":"2011","unstructured":"Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 elicits IFN\u03b3-dependent tumor immune surveillance. Cancer Cell. 2011;20(6):781\u201396.","journal-title":"Cancer Cell"},{"issue":"1","key":"1355_CR31","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane J-P, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136.","journal-title":"Nat Commun"},{"issue":"4","key":"1355_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"1355_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11912-019-0760-z","volume":"21","author":"K Autio","year":"2019","unstructured":"\u2022 Autio K, Oft M. Pegylated interleukin-10: clinical development of an immunoregulatory cytokine for use in cancer therapeutics. Curr Oncol Rep. 2019;21(2):19. (The reviewed discussed the development of pegilodecakin and its application from the context of preclinical investigation and the initial results of the phase I IVY studies in oncology.)","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"1355_CR34","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/S1470-2045(19)30514-5","volume":"20","author":"A Naing","year":"2019","unstructured":"\u2022 Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019;20(11):1544\u20131555b. (This study assessed the safety and activity of pegilodecakin with anti-PD-1 monoclonal antibody inhibitors in patients with advanced solid tumours, including non-small-cell lung cancer, melanoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. The Data cutoff was July 1, 2018.)","journal-title":"Lancet Oncol"},{"issue":"29","key":"1355_CR35","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","volume":"34","author":"A Naing","year":"2016","unstructured":"Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol\u202f: Off J Am Soc Clin Oncol. 2016;34(29):3562\u20139.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"120","key":"1355_CR36","first-page":"2635","volume":"59","author":"V Berk","year":"2012","unstructured":"Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A, et al. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterol. 2012;59(120):2635\u20139.","journal-title":"Hepatogastroenterol"},{"issue":"122","key":"1355_CR37","first-page":"363","volume":"60","author":"JW Chung","year":"2013","unstructured":"Chung JW, Jang HW, Chung MJ, Park JY, Park SW, Chung JB, et al. Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer. Hepatogastroenterol. 2013;60(122):363\u20137.","journal-title":"Hepatogastroenterol"},{"issue":"10","key":"1355_CR38","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","volume":"101","author":"C Yoo","year":"2009","unstructured":"Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101(10):1658\u201363.","journal-title":"Br J Cancer"},{"issue":"4","key":"1355_CR39","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s12032-012-0197-9","volume":"29","author":"M Ghosn","year":"2012","unstructured":"Ghosn M, Saroufim A, Kattan J, Chahine G, Nasr F, Farhat F. Sequential FOLFOX-6 and gemcitabine for locally advanced and\/or metastatic pancreatic cancer. Med Oncol. 2012;29(4):2831\u20137.","journal-title":"Med Oncol"},{"issue":"1","key":"1355_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/s12885-020-07110-x","volume":"20","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg ZA, Feeney K, Lee MA, Mu\u00f1oz A, Graci\u00e1n AC, Lonardi S, et al. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer. 2020;20(1):633.","journal-title":"BMC Cancer"},{"issue":"4_suppl","key":"1355_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.2020.38.4_suppl.96","volume":"38","author":"A Stein","year":"2020","unstructured":"Stein A, Binder M, Goekkurt E, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, et al. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): final results of the phase II AVETUX trial (AIO-KRK-0216). J Clin Oncol. 2020;38(4_suppl):96.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1355_CR42","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2174\/1568009620666200628105727","volume":"20","author":"S Nilsson","year":"2020","unstructured":"Nilsson S, Stein A, Rolfo C, Kranich AL, Mann J, Papadimitriou K, et al. Selinexor (KPT-330), an oral selective inhibitor of nuclear export (SINE) compound, in combination with FOLFOX in patients with metastatic colorectal cancer (mCRC) - final results of the phase I trial SENTINEL. Curr Cancer Drug Targets. 2020;20(10):811\u20137.","journal-title":"Curr Cancer Drug Targets"},{"issue":"15","key":"1355_CR43","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1200\/JCO.2017.76.2187","volume":"36","author":"A Sobrero","year":"2018","unstructured":"Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, et al. FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial. J Clin Oncol. 2018;36(15):1478\u201385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1355_CR44","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s10637-020-01000-6","volume":"39","author":"JR Hecht","year":"2021","unstructured":"\u2022 Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, et al. Immunologic and tumor responses of pegilodecakin with 5-FU\/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021;39(1):182\u201392. (This study assessed the safety and activity of pegilodecakin + FOLFOX in patients with pancreatic ductal adenocarcinoma in an open-label phase 1b trial in the United States.)","journal-title":"Invest New Drugs"},{"key":"1355_CR45","doi-asserted-by":"crossref","unstructured":"\u2022 Hecht JR, Naing A, Falchook GS, Patel MR, Infante JR, Aljumaily R, et al. Overall survival of PEGylated pegilodecakin with 5-FU\/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). 2018;36(15_suppl):4119-. (This study reported on the safety, efficacy and overall survival of AM0010 + FOLFOX as 2nd and later line treatment in pancreatic ductal adenocarcinoma.)","DOI":"10.1200\/JCO.2018.36.15_suppl.4119"},{"issue":"sup1","key":"1355_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","volume":"24","author":"Y Fang","year":"2017","unstructured":"Fang Y, Xue J, Gao S, Lu A, Yang D, Jiang H, et al. Cleavable PEGylation: a strategy for overcoming the \u201cPEG dilemma\u201d in efficient drug delivery. Drug Deliv. 2017;24(sup1):22\u201332.","journal-title":"Drug Deliv"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01355-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T19:54:06Z","timestamp":1674935646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01355-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01355-4","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"assertion":[{"value":"24 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}